2.81  0.4 (16.6%)		06-15 12:10
Open: 2.43 High: 2.84 Volume: 68,563		Pre. Close: 2.41 Low: 2.43 Market Cap: 13(M)

Short term
Mid term
Targets	6-month :	3.94	1-year :	4.61
Resists	First :	3.38	Second :	3.94
Pivot price	2.63
Supports	First :	2.37	Second :	1.75
MAs	MA(5) :	2.44	MA(20) :	2.5
	MA(100) :	3.41	MA(250) :	9.95
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	41.9	D(3) :	37.6
RSI	RSI(14): 54
52-week	High :	31.04	Low :	1.2

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ LNAI ] has closed below upper band by 41.9%. Bollinger Bands are 46.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.8 - 2.81	2.81 - 2.83
Low:	2.37 - 2.39	2.39 - 2.4
Close:	2.38 - 2.41	2.41 - 2.43

Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology.

Thu, 11 Jun 2026
Why Is This Micro-Cap Biotech Stock Up 150% Today? - Stocktwits

Tue, 09 Jun 2026
Lunai Bioworks Inc Stock Short Interest Rises to 62.94% - Quiver Quantitative

Thu, 28 May 2026
Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration - PR Newswire

Thu, 28 May 2026
AI and human brain organoids join forces on Parkinson's, rare epilepsy - Stock Titan

Wed, 20 May 2026
Lunai Bioworks (NASDAQ: LNAI) plans 1-for-8 reverse split to meet Nasdaq price rule - Stock Titan

Wed, 20 May 2026
LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	5 (M)
Held by Insiders	3.35e+006 (%)
Held by Institutions	31.2 (%)
Shares Short	207 (K)
Shares Short P.Month	0 (K)

EPS	-9.77e+006
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-6 %
Return on Assets (ttm)	815.2 %
Return on Equity (ttm)	-9.7 %
Qtrly Rev. Growth	20940 %
Gross Profit (p.s.)	0
Sales Per Share	-904.06
EBITDA (p.s.)	58166.7
Qtrly Earnings Growth	-61.6 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.01
Price to Cash Flow	-0.47

Dividend	0
Forward Dividend	345110
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.